An anonymous reader quotes a report from Wired: More than 70 civil liberties, domestic violence, reproductive rights, LGBTQ+, labor, and immigrant advocacy organizations are demanding that Meta abandon plans to deploy face recognition on its Ray-Ban and Oakley smart glasses, warning that the feature -- reportedly known inside the company as "Name Tag" -- would hand stalkers, abusers, and federal agents the ability to silently identify strangers in public. The coalition, which includes the ACLU, the Electronic Privacy Information Center, Fight for the Future, Access Now, and the Leadership Conference on Civil and Human Rights, is demanding Meta kill the feature before launch, after internal documents surfaced showing the company hoped to use the current "dynamic political environment" as cover for the rollout, betting that civil society groups would have their resources "focused on other concerns."

Name Tag, as revealed in February by The New York Times, would work through the artificial intelligence assistant built into Meta's smart glasses, allowing wearers to pull up information about people in their field of view. Engineers have reportedly been weighing two versions of the feature: one that would only identify people the wearer is already connected to on a Meta platform, and a broader version that could recognize anyone with a public account on a Meta service such as Instagram. The coalition wants Meta to scrap the feature entirely. In a letter to CEO Mark Zuckerberg on Monday, it argues that face recognition in inconspicuous consumer eyewear "cannot be resolved through product design changes, opt-out mechanisms, or incremental safeguards." Bystanders in public have no meaningful way to consent to being identified, it says.

Meta is also urged to disclose any known instances of its wearables being used in stalking, harassment, or domestic violence cases; disclose any past or ongoing discussions with federal law enforcement agencies, including Immigration and Customs Enforcement and Customs and Border Protection, about the use of Meta wearables or data from them; and commit to consulting civil society and independent privacy experts before integrating biometric identification into any consumer device. "People should be able to move through their daily lives without fear that stalkers, scammers, abusers, federal agents, and activists across the political spectrum are silently and invisibly verifying their identities and potentially matching their names to a wealth of readily available data about their habits, hobbies, relationships, health, and behaviors," write the groups, which also include Common Cause, Jane Doe Inc., UltraViolet, the National Organization for Women, the New York State Coalition Against Domestic Violence, the Library Freedom Project, and Old Dykes Against Billionaire Tech Bros, among others.

Longtime Slashdot reader walterbyrd shares a report from ABC News: In a study of nearly 28 million older Americans, long-term exposure to fine particle air pollution raised the risk of Alzheimer's disease. That link held even after researchers accounted for common conditions like high blood pressure, stroke and depression. Fine particle air pollution, known as PM2.5, consists of tiny particles in the air that come from car exhaust, power plants, wildfires, and burning fuels, according to the American Lung Association. They are small enough to travel deep into the lungs and even reach the bloodstream.

The research, conducted at Emory University and published in PLOS Medicine, tracked health data over nearly two decades to explore whether air pollution harms the brain indirectly by causing high blood pressure or heart disease, which, in turn, leads to dementia. However, these "middleman" conditions accounted for less than 5% of the connection between pollution and Alzheimer's, the research found. The researchers say this suggests that over 95% of the Alzheimer's risk comes from the direct impact of breathing in dirty air, likely through inflammation or damage to brain cells. "The relationship between PM2.5 and AD [Alzheimer's disease] has been shown to be pretty much linear," said Kyle Steenland, a professor in the departments of environmental health and epidemiology at the Rollins School of Public Health at Emory University, and senior author of the study. "The reason this is particularly important is that PM2.5 is known to be associated with high blood pressure, stroke and depression -- all of which are associated with AD. So, from a prevention standpoint, simply treating these diseases will not get rid of the problem. We have to address exposure to PM2.5."

Up to a third of people worldwide have shoulder pain; it's one of the most common musculoskeletal complaints. But medical imaging might not reveal the problem -- in fact, it could even cloud it. From a report: In a study published in JAMA Internal Medicine this week, 99 percent of adults over 40 were found to have at least one abnormality in a rotator cuff on magnetic resonance imaging (MRI). The rotator cuff is the group of muscles and tendons in a shoulder joint that keeps the upper arm bone securely in the shoulder socket -- and is often blamed for pain and other symptoms.

The trouble is, the vast majority of the people in the study had no problems with their shoulders. The finding calls into question the growing use of MRIs to try to diagnose shoulder pain -- and, in turn, the growing problem of overtreatment of rotator cuff (RC) abnormalities, which includes partial- and full-thickness tears as well as signs of tendinopathy (tendon swelling and thickening). "While we cannot dismiss the possibility that some RC tears may contribute to shoulder symptoms, our findings indicate that we are currently unable to distinguish clinically meaningful MRI abnormalities from incidental findings," the study authors concluded.

Ultra-processed foods (UPFs) have more in common with cigarettes than with fruit or vegetables, and require far tighter regulation, according to a new report. The Guardian: UPFs and cigarettes are engineered to encourage addiction and consumption, researchers from three US universities said, pointing to the parallels in widespread health harms that link both.

UPFs, which are widely available worldwide, are food products that have been industrially manufactured, often using emulsifiers or artificial colouring and flavours. The category includes soft drinks and packaged snacks such as crisps and biscuits. There are similarities in the production processes of UPFs and cigarettes, and in manufacturers' efforts to optimise the "doses" of products and how quickly they act on reward pathways in the body, according to the paper from researchers at Harvard, the University of Michigan and Duke University.

They draw on data from the fields of addiction science, nutrition and public health history to make their comparisons, published on 3 February in the healthcare journal the Milbank Quarterly. The authors suggest that marketing claims on the products, such as being "low fat" or "sugar free," are "health washing" that can stall regulation, akin to the advertising of cigarette filters in the 1950s as protective innovations that "in practice offered little meaningful benefit."

An anonymous reader quotes a report from Science.org: Some 10,109 doctoral-trained experts in science and related fields left their jobs last year as President Donald Trump dramatically shrank the overall federal workforce. That exodus was only 3% of the 335,192 federal workers who exited last year but represents 14% of the total number of Ph.D.s in science, technology, engineering, and math (STEM) or health fields employed at the end of 2024 as then-President Joe Biden prepared to leave office. The numbers come from employment data posted earlier this month by the White House Office of Personnel Management (OPM). At 14 research agencies Science examined in detail, departures outnumbered new hires last year by a ratio of 11 to one, resulting in a net loss of 4224 STEM Ph.D.s. The graphs that follow show the impact is particularly striking at such scientist-rich agencies as the National Science Foundation (NSF). But across the government, these departing Ph.D.s took with them a wealth of subject matter expertise and knowledge about how the agencies operate.

[...] Science's analysis found that reductions in force, or RIFs, accounted for relatively few departures in 2025. Only at the Centers for Disease Control and Prevention, where 16% of the 519 STEM Ph.D.s who left last year got pink RIF slips, did the percentage exceed 6%, and some agencies reported no STEM Ph.D. RIFs in 2025. At most agencies, the most common reasons for departures were retirements and quitting. Although OPM classifies many of these as voluntary, outside forces including the fear of being fired, the lure of buyout offers, or a profound disagreement with Trump policies, likely influenced many decisions to leave. Many Ph.D.s departed because their position was terminated.

An anonymous reader quotes a report from Bloomberg: Oracle is trying -- and sometimes struggling -- to attract workers to Nashville, where it is developing a massive riverfront headquarters. The company is hiring for more roles in Nashville than any other US city, with a special focus on jobs in its crucial cloud infrastructure unit. Oracle cloud workers based elsewhere say they've been offered tens of thousands of dollars in incentives to move. Chairman Larry Ellison made a splash in April 2024 when he said Oracle would make Nashville its "world headquarters" just a few years after moving the software company from Redwood City, California, to Austin. His proclamation followed a 2021 tax incentive deal in which Oracle pledged to create 8,500 jobs in Nashville by 2031, paying an average salary above six figures.

"We're creating a world leading cloud and AI hub in Nashville that is attracting top talent locally, regionally, and from across the country," Oracle Senior Vice President Scott Twaddle said in a statement. "We've seen great success recruiting engineering and technical positions locally and will continue to hire aggressively for the next several years." Still, Oracle has a long way to go in its hiring goals. Today, it has about 800 workers assigned to offices in Nashville, according to documents seen by Bloomberg. That trails far behind the number of company employees in locations including Redwood City, Austin and Kansas City, the center of health records company Cerner, which Oracle acquired in 2022.

A lack of state income tax and the city's thriving music scene are touted by Oracle's promotional materials to attract talent to Nashville. Some new hires note they moved because in a tough tech job market, the Tennessee city was the only place with an Oracle position offered. To fit all of these workers, Oracle is planning a massive campus along the Cumberland River. It will feature over 2 million square feet of office space, a new cross-river bridge and a branch of the ultra high-end sushi chain Nobu, which has locations on many properties connected to Ellison, including the Hawaiian island of Lanai. [...] Oracle has been running recruitment events for the new hub. But a common concern for employees weighing a move is that Nashville is classified by Oracle in a lower geographic pay band than California or Seattle, meaning that future salary growth is likely limited, according to multiple workers who asked not to be identified discussing private information.

A weaker local tech job market also gives pause to some considering relocation. In addition, many of the roles in Nashville require five days a week in the office, which is a shift for Oracle, where a significant number of roles are remote. For a global company like Oracle, the exact meaning of "headquarters" can be a bit unclear. Austin remains the address included on company SEC filings and its executives are scattered across the country. The city where Oracle is hiring for the most positions globally is Bengaluru, the southern Indian tech hub. Still, Oracle is positioning Nashville to be at the center of its future. "We're developing our Nashville location to stand alongside Austin, Redwood Shores, and Seattle as a major innovation hub," Oracle writes on its recruitment site. "This is your chance to be part of it."

An anonymous reader quotes a report from the Guardian: High-profile studies reporting the presence of microplastics throughout the human body have been thrown into doubt by scientists who say the discoveries are probably the result of contamination and false positives. One chemist called the concerns "a bombshell." Studies claiming to have revealed micro and nanoplastics in the brain, testes, placentas, arteries and elsewhere were reported by media across the world, including the Guardian.

There is no doubt that plastic pollution of the natural world is ubiquitous, and present in the food and drink we consume and the air we breathe. But the health damage potentially caused by microplastics and the chemicals they contain is unclear, and an explosion of research has taken off in this area in recent years. However, micro- and nanoplastic particles are tiny and at the limit of today's analytical techniques, especially in human tissue. There is no suggestion of malpractice, but researchers told the Guardian of their concern that the race to publish results, in some cases by groups with limited analytical expertise, has led to rushed results and routine scientific checks sometimes being overlooked.

The Guardian has identified seven studies that have been challenged by researchers publishing criticism in the respective journals, while a recent analysis listed 18 studies that it said had not considered that some human tissue can produce measurements easily confused with the signal given by common plastics. There is an increasing international focus on the need to control plastic pollution but faulty evidence on the level of microplastics in humans could lead to misguided regulations and policies, which is dangerous, researchers say. It could also help lobbyists for the plastics industry to dismiss real concerns by claiming they are unfounded. While researchers say analytical techniques are improving rapidly, the doubts over recent high-profile studies also raise the questions of what is really known today and how concerned people should be about microplastics in their bodies.

South Korea's President Lee Jae Myung asked at a televised policy meeting last month whether the country's state-run healthcare plan could cover hair-loss treatment, framing it as a question about whether hair loss qualifies as a disease. The health minister told Lee that baldness is generally considered an aesthetic problem and therefore covered out-of-pocket, but the 61-year-old president -- who himself has a full head of hair -- pushed back, arguing that young people experiencing thinning hair view their situation as a "matter of survival."

The proposal has divided the country. South Korea is known for a cultural phenomenon called "lookism," where physical appearance carries significant weight in professional and social settings. The expression "your appearance is also a credential" is common, and nearly all job applications require a photograph, including those for part-time barista positions.

Lee first made the pledge to cover hair-loss treatment during his unsuccessful 2022 presidential campaign but dropped it when he ran again. He won a snap election in June and has now resurrected the idea as a way to appeal to younger voters who have grown more dissatisfied with him. The Korean Medical Association has called the proposal "questionable" given the health system's stretched finances. The health ministry is currently reviewing whether the treatments are appropriate for coverage. More than three in four South Koreans believe everyone has concerns about hair loss, according to a recent Embrain Trend Monitor poll.

"I believe artificial intelligence will displace workers at a scale many people don't yet realize," says Sal Kahn (founder/CEO of the nonprofit Khan Academy). But in an op-ed in the New York Times he also proposes a solution that "could change the trajectory of the lives of millions who will be displaced..."

"I believe that every company benefiting from automation — which is most American companies — should... dedicate 1 percent of its profits to help retrain the people who are being displaced." This isn't charity. It is in the best interest of these companies. If the public sees corporate profits skyrocketing while livelihoods evaporate, backlash will follow — through regulation, taxes or outright bans on automation. Helping retrain workers is common sense, and such a small ask that these companies would barely feel it, while the public benefits could be enormous...

Roughly a dozen of the world's largest corporations now have a combined profit of over a trillion dollars each year. One percent of that would create a $10 billion annual fund that, in part, could create a centralized skill training platform on steroids: online learning, ways to verify skills gained and apprenticeships, coaching and mentorship for tens of millions of people. The fund could be run by an independent nonprofit that would coordinate with corporations to ensure that the skills being developed are exactly what are needed. This is a big task, but it is doable; over the past 15 years, online learning platforms have shown that it can be done for academic learning, and many of the same principles apply for skill training.
"The problem isn't that people can't work," Khan writes in the essay. "It's that we haven't built systems to help them continue learning and connect them to new opportunities as the world changes rapidly." To meet the challenges, we don't need to send millions back to college. We need to create flexible, free paths to hiring, many of which would start in high school and extend through life. Our economy needs low-cost online mechanisms for letting people demonstrate what they know. Imagine a model where capability, not how many hours students sit in class, is what matters; where demonstrated skills earn them credit and where employers recognize those credits as evidence of readiness to enter an apprenticeship program in the trades, health care, hospitality or new categories of white-collar jobs that might emerge...

There is no shortage of meaningful work — only a shortage of pathways into it.
Thanks to long-time Slashdot reader destinyland for sharing the article.

Today America's college professors "struggle to accommodate the many students with an official disability designation," reports the Atlantic, "which may entitle them to extra time, a distraction-free environment, or the use of otherwise-prohibited technology."

Their staff writer argues these accommodations "have become another way for the most privileged students to press their advantage." [Over the past decade and a half] the share of students at selective universities who qualify for accommodations — often, extra time on tests — has grown at a breathtaking pace. At the University of Chicago, the number has more than tripled over the past eight years; at UC Berkeley, it has nearly quintupled over the past 15 years. The increase is driven by more young people getting diagnosed with conditions such as ADHD, anxiety, and depression, and by universities making the process of getting accommodations easier. The change has occurred disproportionately at the most prestigious and expensive institutions. At Brown and Harvard, more than 20 percent of undergraduates are registered as disabled. At Amherst, that figure is 34 percent. Not all of those students receive accommodations, but researchers told me that most do. The schools that enroll the most academically successful students, in other words, also have the largest share of students with a disability that could prevent them from succeeding academically. "You hear 'students with disabilities' and it's not kids in wheelchairs," one professor at a selective university, who requested anonymity because he doesn't have tenure, told me. "It's just not. It's rich kids getting extra time on tests...."

Recently, mental-health issues have joined ADHD as a primary driver of the accommodations boom. Over the past decade, the number of young people diagnosed with depression or anxiety has exploded. L. Scott Lissner, the ADA coordinator at Ohio State University, told me that 36 percent of the students registered with OSU's disability office have accommodations for mental-health issues, making them the largest group of students his office serves. Many receive testing accommodations, extensions on take-home assignments, or permission to miss class. Students at Carnegie Mellon University whose severe anxiety makes concentration difficult might get extra time on tests or permission to record class sessions, Catherine Samuel, the school's director of disability resources, told me. Students with social-anxiety disorder can get a note so the professor doesn't call on them without warning... Some students get approved for housing accommodations, including single rooms and emotional-support animals. Other accommodations risk putting the needs of one student over the experience of their peers. One administrator told me that a student at a public college in California had permission to bring their mother to class. This became a problem, because the mom turned out to be an enthusiastic class participant. Professors told me that the most common — and most contentious — accommodation is the granting of extra time on exams...

Several of the college students I spoke with for this story said they knew someone who had obtained a dubious diagnosis... The surge itself is undeniable. Soon, some schools may have more students receiving accommodations than not, a scenario that would have seemed absurd just a decade ago. Already, at one law school, 45 percent of students receive academic accommodations. Paul Graham Fisher, a Stanford professor who served as co-chair of the university's disability task force, told me, "I have had conversations with people in the Stanford administration. They've talked about at what point can we say no? What if it hits 50 or 60 percent? At what point do you just say 'We can't do this'?" This year, 38 percent of Stanford undergraduates are registered as having a disability; in the fall quarter, 24 percent of undergraduates were receiving academic or housing accommodations.

An anonymous reader quotes a report from the Associated Press: They're cute, even cuddly, and promise learning and companionship -- but artificial intelligence toys are not safe for kids, according to children's and consumer advocacy groups urging parents not to buy them during the holiday season. These toys, marketed to kids as young as 2 years old, are generally powered by AI models that have already been shown to harm children and teenagers, such as OpenAI's ChatGPT, according to an advisory published Thursday by the children's advocacy group Fairplay and signed by more than 150 organizations and individual experts such as child psychiatrists and educators.

"The serious harms that AI chatbots have inflicted on children are well-documented, including fostering obsessive use, having explicit sexual conversations, and encouraging unsafe behaviors, violence against others, and self-harm," Fairplay said. AI toys, made by companies including Curio Interactive and Keyi Technologies, are often marketed as educational, but Fairplay says they can displace important creative and learning activities. They promise friendship but disrupt children's relationships and resilience, the group said. "What's different about young children is that their brains are being wired for the first time and developmentally it is natural for them to be trustful, for them to seek relationships with kind and friendly characters," said Rachel Franz, director of Fairplay's Young Children Thrive Offline Program. Because of this, she added, the trust young children are placing in these toys can exacerbate the types of harms older children are already experiencing with AI chatbots.

A separate report Thursday by Common Sense Media and psychiatrists at Stanford University's medical school warned teenagers against using popular AI chatbots as therapists. Fairplay, a 25-year-old organization formerly known as the Campaign for a Commercial-Free Childhood, has been warning about AI toys for years. They just weren't as advanced as they are today. A decade ago, during an emerging fad of internet-connected toys and AI speech recognition, the group helped lead a backlash against Mattel's talking Hello Barbie doll that it said was recording and analyzing children's conversations. This time, though AI toys are mostly sold online and more popular in Asia than elsewhere, Franz said some have started to appear on store shelves in the U.S. and more could be on the way. "Everything has been released with no regulation and no research, so it gives us extra pause when all of a sudden we see more and more manufacturers, including Mattel, who recently partnered with OpenAI, potentially putting out these products," Franz said. Last week, consumer advocates at U.S. PIRG called out the trend of buying AI toys in its annual "Trouble in Toyland" report. This year, the organization tested four toys that use AI chatbots. "We found some of these toys will talk in-depth about sexually explicit topics, will offer advice on where a child can find matches or knives, act dismayed when you say you have to leave, and have limited or no parental controls," the report said.

An anonymous reader shared this report from the Guardian: The number of deaths linked to superbugs that do not respond to frontline antibiotics increased by 17% in England last year, according to official figures that raise concerns about the ongoing increase in antimicrobial resistance.

The figures, released by the UK Health Security Agency, also revealed a large rise in private prescriptions for antibiotics, with 22% dispensed through the private sector in 2024. The increase in private prescribing is partly explained by the Pharmacy First scheme, a flagship policy of Rishi Sunak's government that allows patients to be prescribed antibiotics for common illnesses without seeing a GP, raising questions about whether the shift in prescribing patterns risks contributing to the rise in resistance.

"Antibiotic resistance is one of the greatest health threats we face," said the UKHSA's chief executive, Prof Susan Hopkins. "More people than ever are acquiring infections that cannot be effectively treated by antibiotics. This puts them at greater risk of serious illness and even death, with our poorest communities hit the hardest... It's positive that we've seen antibiotic use fall in England within the NHS but we need to go further, faster," said Hopkins.

"Please remember to only take antibiotics if you have been told to do so by a healthcare professional. Do not save some for later or share them with friends and family. If you have leftover antibiotics, please bring them to a pharmacy for appropriate disposal."

One of the most common viruses in the world could be the cause of lupus, an autoimmune disease with wide-ranging symptoms, according to a new study. From a report: Until now, lupus was somewhat mysterious: No single root cause of the disease had been found, and while there is no cure, there are medications that can treat it.

The research, published in the journal Science Translational Medicine, suggests that Epstein-Barr virus -- which 95% of people acquire at some point in life -- could cause lupus by driving the body to attack its own healthy cells.

It adds to mounting evidence that Epstein-Barr is associated with multiple long-term health issues, including other autoimmune conditions. As this evidence stacks up, scientists have accelerated calls for a vaccine that targets the virus.

"If we now better understand how this fastidious virus is responsible for autoimmune diseases, I think it's time to figure out how to prevent it," said Dr. Anca Askanase, clinical director of the Lupus Center at Columbia University, who wasn't involved in the new research.

The proliferation of difficult-to-treat bacterial diseases represents a growing threat, according to the World Health Organization's (WHO) Global Antibiotic Resistance Surveillance Report. Wired: The report reveals that, between 2018 and 2023, antibiotic resistance increased by more than 40 percent in monitored pathogen-drug combinations, with an average annual increase of 5-15 percent. According to data reported by more than 100 countries to WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), one in six laboratory-confirmed bacteria in 2023 proved resistant to antibiotic treatment, all related to various common diseases globally.

For the first time, this edition of the report includes prevalence estimates of resistance to 22 antibiotics used to treat urinary tract, gastrointestinal, bloodstream, and gonorrheal conditions. The analysis focused on eight common pathogens: Acinetobacter spp, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae, non-typhoidal Salmonella spp, Shigella spp, Staphylococcus aureus, and Streptococcus pneumoniae. The results show that resistant gram-negative bacteria pose the greatest threat. Of particular note are Escherichia coli and Klebsiella pneumoniae, which are associated with bloodstream infections that can lead to sepsis, organ failure, and death. "More than 40 percent of E. coli and more than 55 percent of K. pneumoniae strains worldwide are now resistant to third-generation cephalosporins, the first-choice treatment for these types of infections," the report warns.

Amazon Pharmacy will begin offering prescription pickup kiosks at its One Medical clinics starting in Los Angeles this December, allowing patients to collect common medications like antibiotics and inhalers without waiting for delivery. Reuters reports: The kiosks will be the first in-person pick-up service offered by Amazon Pharmacy, which has been providing prescription services primarily by delivery, said Hannah McClellan Richards, a vice president at Amazon Pharmacy. One Medical offers a membership structure that allows patients to access primary and urgent care at a subscription fee of $199 annually. Patients without a membership are still able to book an appointment and would be able to use the kiosk, the company said.

Richards said in an interview that the company plans to expand the kiosk model outside of California in 2026 and is in talks with external health systems to introduce the machines through partnerships. Amazon does not plan to offer medicines that must be refrigerated, such as GLP-1 weight-loss drugs, or more tightly regulated prescriptions like controlled pain medicines through the kiosk. Inventory for each kiosk will be tailored to the provider, and patients would be able to consult a company pharmacist virtually, Amazon said in a press release.

The oldest person living in Japan is 114 years old, reports the BBC. But "The number of people in Japan aged 100 or older has risen to a record high of nearly 100,000, its government has announced." Setting a new record for the 55th year in a row, the number of centenarians in Japan was 99,763 as of September, the health ministry said on Friday. Of that total, women accounted for an overwhelming 88%... Health minister Takamaro Fukoka congratulated the 87,784 female and 11,979 male centenarians on their longevity and expressed his "gratitude for their many years of contributions to the development of society"....

The higher life expectancy is mainly attributed to fewer deaths from heart disease and common forms of cancer, in particular breast and prostate cancer. Japan has low rates of obesity, a major contributing factor to both diseases, thanks to diets low in red meat and high in fish and vegetables. The obesity rate is particularly low for women, which could go some way to explaining why Japanese women have a much higher life expectancy than their male counterparts... But it's not just diet. Japanese people tend to stay active into later life, walking and using public transport more than elderly people in the US and Europe...

However, several studies have cast doubt on the validity of global centenarian numbers, suggesting data errors, unreliable public records and missing birth certificates may account for elevated figures. A government audit of family registries in Japan in 2010 uncovered more than 230,000 people listed as being aged 100 or older who were unaccounted for, some having in fact died decades previously. The miscounting was attributed to patchy record-keeping and suspicions that some families may have tried to hide the deaths of elderly relatives in order to claim their pensions.

An anonymous reader quotes a report from the Associated Press: LSD reduced symptoms of anxiety in a midstage study published Thursday, paving the way for additional testing and possible medical approval of a psychedelic drug that has been banned in the U.S. for more than a half century. The results from drugmaker Mindmed tested several doses of LSD in patients with moderate-to-severe generalized anxiety disorder, with the benefits lasting as long as three months. The company plans to conduct follow-up studies to confirm the results and then apply for Food and Drug Administration approval. [...]

For the study, researchers measured anxiety symptoms in nearly 200 patients who randomly received one of four doses of LSD or a placebo. The main aim was to find the optimal dose of the drug, which can cause intense visual hallucinations and occasionally feelings of panic or paranoia. At four weeks, patients receiving the two highest doses had significantly lower anxiety scores than those who received placebo or lower doses. After 12 weeks, 65% of patients taking the most effective LSD dose -- 100 micrograms -- continued to show benefits and nearly 50% were deemed to be in remission. The most common side effects included hallucinations, nausea and headaches.

Patients who got dummy pills also improved -- a common phenomenon in psychedelic and psychiatric studies -- but their changes were less than half the size those getting the real drug. The research was not immune to problems seen in similar studies. Most patients were able to correctly guess whether they'd received LSD or a dummy pill, undercutting the "blinded" approach that's considered critical to objectively establishing the benefits of a new medicine. In addition, a significant portion of patients in both the placebo and treatment groups dropped out early, narrowing the final data set. It also wasn't clear how long patients might continue to benefit. If the two trials are successful, Mindmed will submit them for FDA approval.

"It's possible that some people may need retreatment," said Dr. Maurizio Fava of Mass General Brigham Hospital, the study's lead author and an adviser to Mindmed. "How many retreatments, we don't know yet, but the long-lasting effect is quite significant."

The study has been published in the Journal of the American Medical Association.

An anonymous reader quotes a report from The Guardian: Fine-particulate air pollution can drive devastating forms of dementia by triggering the formation of toxic clumps of protein that destroy nerve cells as they spread through the brain, research suggests. Exposure to the airborne particles causes proteins in the brain to misfold into the clumps, which are hallmarks of Lewy body dementia, the second most common form of dementia after Alzheimer's disease. The finding has "profound implications" for preventing the neurodegenerative disorder, which affects millions worldwide, with scientists calling for a concerted effort to improve air quality by cutting emissions from industrial activity and vehicle exhausts, improving wildfire management and reducing wood burning in homes.

The researchers began by analyzing hospital records of the 56.5 million US Medicare patients. They looked at those who were admitted for the first time between 2000 and 2014 with the protein damage. Armed with the patients' zip codes, the scientists estimated their long-term exposure to PM2.5 pollution, airborne particles that are smaller than 2.5 thousandths of a millimeter. These can be inhaled deep into the lungs and are found in the bloodstream, brain and other organs. They found that long-term exposure to PM2.5 raised the risk of Lewy body dementia, but had less of an impact on rates of another neurodegenerative brain disease that is not driven by the toxic proteins. Lewy bodies are made from a protein called alpha-synuclein. The protein is crucial for healthy brain functioning, but can misfold in various ways to produce different kinds of harmful Lewy bodies. These can kill nerve cells and cause devastating disease by spreading through the brain.

To see if air pollution could trigger Lewy bodies, the team exposed mice to PM2.5 pollution every other day for 10 months. Some were normal mice, but others were genetically modified to prevent them making alpha-synuclein. The results were striking: in normal mice, nerve cells died off, leading to brain shrinkage and cognitive decline. The genetically modified mice were largely unaffected. Further work in mice showed that PM2.5 pollution drove the formation of aggressive, resilient and toxic clumps of alpha-synuclein clumps that looked very similar to Lewy bodies in humans. Although the work is in mice, the findings are considered compelling evidence. The work has been published in the journal Science.

alternative_right shares a report from ScienceAlert: The insecticide chlorpyrifos is a powerful tool for controlling various pests, making it one of the most widely used pesticides during the latter half of the 20th century. Like many pesticides, however, chlorpyrifos lacks precision. In addition to harming non-target insects like bees, it has also been linked to health risks for much larger animals -- including us. Now, a new US study suggests those risks may begin before birth. Humans exposed to chlorpyrifos prenatally are more likely to exhibit structural brain abnormalities and reduced motor functions in childhood and adolescence.

Progressively higher prenatal exposure to chlorpyrifos was associated with incrementally greater deviations in brain structure, function, and metabolism in children and teens, the researchers found, along with poorer measures of motor speed and motor programming. [...] This supports previous research linking chlorpyrifos with impaired cognitive function and brain development, but these findings are the first evidence of widespread and long-lasting molecular, cellular, and metabolic effects in the brain. "The disturbances in brain tissue and metabolism that we observed with prenatal exposure to this one pesticide were remarkably widespread throughout the brain," says first author Bradley Peterson, a developmental neuroscientist at the University of Southern California's Keck School of Medicine. Senior author Virginia Rauh added: "It is vitally important that we continue to monitor the levels of exposure in potentially vulnerable populations, especially in pregnant women in agricultural communities, as their infants continue to be at risk."

The report notes that the EPA banned residential use of chlorpyrifos in 2001 but the pesticide is still used in agriculture around the world.

The findings have been published in the journal JAMA Neurology.

"The U.S. is currently home to more than 18 million cancer survivors," reports the Wall Street Journal, "over 5% of the total population" (including those who are living with the disease).

Their article tells the story of Gwen Orilio, who was diagnosed with stage-four lung cancer at age 31. Ten years later she's still alive — and she still has metastatic cancer... Keeping her going is a string of new treatments that don't cure the disease but can buy months — even years — of time, with the hope that once one drug stops working a new one will come along. Orilio started on chemotherapy, and then switched to a new treatment, and then another, and another, and another... A small but growing population is living longer with incurable or advanced cancer, navigating the rest of their lives with a disease increasingly akin to a chronic illness. The trend, which started in breast cancer, has expanded to patients with melanoma, kidney cancer, lung cancer and others. The new drugs can add years to a life, even for some diagnoses like Orilio's that were once swift death sentences. They also put people in a state of limbo, living on a knife's edge waiting for the next scan to say a drug has stopped working and doctors need to find a new one. The wide range of survival times has made it more difficult for cancer doctors to predict how much time a patient might have left. For most, the options eventually run out....

More than 690,000 people were projected to be living with stage-four or metastatic disease of the six most common cancers — melanoma, breast, bladder, colorectal, prostate or lung cancer — in 2025, according to a 2022 report from the National Cancer Institute. That's an increase from 623,000 in 2018 and a significant rise since 1990, the report found... Nearly 30% of survivors diagnosed with metastatic melanoma and 20% of those diagnosed with metastatic colorectal or breast cancer had been living with their disease for a decade or more, the NCI paper estimated... Even for lung cancer, the biggest U.S. cancer killer, the five-year relative survival rate for advanced disease has inched up, from 3.7% for patients diagnosed in 2004 to 9.2% for patients diagnosed in 2017, federal data show. The overall lung cancer survival rate has risen by 26% in the past five years, according to the American Lung Association, as declining cigarette use, screening and new drugs have driven down deaths.

The expanding number of therapies that target a cancer's mutations or boost the immune system are improving the outlook for several cancers. In breast cancer, treatment for metastatic disease accounted for 29% of the drop in deaths between 1975 and 2019, according to one 2024 estimate, with screening and treatment for early-stage disease accounting for the rest.
The number of American cancer survivors (or those living with cancer) is expected to grow to 26 million by 2040," the article points out.